Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study

Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer[...]

ElHarouni D, Al-Jazrawe M, Choi S, Dede M, Hinoue T, Misek SA, Noh H, Zanella L, Tseng YY, Francies HE, Plenker D, Kyi CW, Perez-Mayoral[...]

Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]